|
The following stocks are the leading risers and fallers on AIM on Friday. ---------- AIM - WINNERS ---------- Proteome Sciences PLC, up 11% at 4.98 pence, 12-month range 2.22p-5.00p. The protein-focused drug development services provider wins a new deal with a US biopharmaceutical company. The customer is using Proteome’s spectrometry services for the analysis of samples from an ongoing clinical probe. ‘This project will be provided utilising the good clinical laboratory practice accreditation obtained by Proteome Sciences specifically for this type of project. The contract value is in excess of $1 million and the company considers that a significant proportion of the work should be completed in the current financial year and into 2026,’ Proteome says. ---------- AIM - LOSERS ---------- Biome Technologies PLC, down 47% at 1.98p, 12-month range 1.42p-130.00p. It proposes an exit from London’s junior market. The regulatory and cost ‘burden’ of an AIM listing, as well as the likely challenge in raising ‘significant equity through public markets’ are reasons the bioplastics producer gives. Shareholders will vote on the proposed delisting on March 31. If approved, it will exit on March 21. Biome says it has received the support of just under 83% of shareholders for the delisting. Afterwards, it will make its shares available for trading on the matched bargain facility offered by JP Jenkins. ---------- Poolbeg Pharma PLC, down 21% at 3.80p, 12-month range 3.55p-15.77p. Poolbeg is ‘surprised and disappointed’ by Hookipa Pharma Inc opting against making a bid for the company. In a brief statement late Thursday, Hookipa Pharma, a Nasdaq-listed biopharmaceutical company with a $21.8 million market capitalisation, said ‘it does not intend to make an offer for Poolbeg’. ‘Non-binding’ and ‘non-exclusive’ talks between the two firms were announced in early January. Under the proposed terms announced in January, shareholders in Poolbeg would have received 0.03 of a Hookipa share for each Poolbeg share. Poolbeg Executive Chair Cathal Friel says Friday: ‘We were surprised and disappointed to hear of Hookipa’s decision to withdraw from the combination discussions. Throughout this process, we have seen strong interest in the potential of POLB 001 and we continue to be focused on maximising the potential of our in-house programmes and exploring new opportunities to generate value for our shareholders.’ ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
